Mereo BioPharma (MREO): Analyst Targets Suggest +450% Upside Potential

Key Takeaways

• The $1.60 central target is the arithmetic mean of four verified analyst price targets issued after the December 2025 Phase 3 setback.
• At a recent price near $0.29, reaching $1.60 would require a gain of roughly 450%, a very large move.
• The individual targets range widely, from $0.50 (Jefferies) to $3.00 (Needham), reflecting deep disagreement about the path forward.
• The strongest supports are a cash runway into mid-2027, statistically significant bone-mineral-density (BMD) results, and a Phase 3-ready second program.
• The biggest risks are the missed fracture endpoints, regulatory uncertainty, potential dilution, and dependence on partner Ultragenyx.
• You can find more detail on the company's Major News, Today's Price Move, Forecast, and Earnings pages.

Analyst Targets After the Setback

Four post-failure analyst price targets were reviewed. Jefferies downgraded to Hold with a $0.50 target on December 30, 2025; BTIG trimmed its target to $1.00 while keeping a Buy rating; Leerink Partners held Buy with a $2.00 target; and Needham lowered its target to $3.00 on January 13, 2026, while retaining Buy. The average of these four comes to roughly $1.63, which rounds to the $1.60 central target, with a spread from $0.50 to $3.00. Earlier targets were much higher, such as JPMorgan’s $8.00 Overweight from August 2025, but those predate the Phase 3 results and are now considered outdated.

The wide dispersion shows real differences in outlook. Some analysts see the missed primary endpoints as a major blow to commercial prospects, while others highlight the positive BMD secondary data and the FDA’s willingness to consider alternative fracture analyses. I also checked this using Tickeron’s AI Screener to compare the stock’s positioning within the sector.

Current Price and Required Move

With shares trading near $0.29, the gap to $1.60 implies roughly 450% upside. That kind of advance would not stem from routine updates but from a meaningful re-rating, most likely tied to regulatory clarity on setrusumab, a decision on its BLA path, or a productive partnership for alvelestat. Cash stood at about $41 million at the end of 2025, with runway guidance into mid-2027, which lowers near-term liquidity concerns even as the company continues to operate at a loss.

Factors That Could Support Higher Prices

• Cash runway: Guidance through mid-2027 gives time to explore regulatory and partnering avenues.
• BMD secondary endpoint: Both Phase 3 trials delivered statistically significant bone-mineral-density gains, and the FDA has indicated openness to alternative fracture endpoints.
• Alvelestat: A Phase 3-ready program in alpha-1 antitrypsin deficiency-associated lung disease is advancing toward potential partnering.
• Unmet medical need: No broadly approved treatments exist for osteogenesis imperfecta, which could factor into regulatory and partner decisions.

Risks That Could Limit Upside

• Missed primary endpoints: Setrusumab failed its fracture-rate primary goals, the key hurdle for approval.
• Regulatory uncertainty: Talks with the FDA and UK MHRA continue, but no clear approval pathway has been established.
• Financing needs: A clinical-stage firm may require additional capital, which could pressure the ADR price.
• Partner reliance: Ultragenyx leads global development of setrusumab, limiting Mereo’s direct control.
• Analyst divergence: The spread from $0.50 to $3.00 underscores how much remains unresolved.

Technical Picture and Key Levels

The ADRs sit near the bottom of a 52-week range between roughly $0.20 and $2.37. The drop from above $2.00 has created substantial overhead supply. The $0.50 and $1.00 levels stand out as near-term hurdles that would need to be cleared before a move toward $1.60 looks more feasible. The overall trend remains bearish without a clear fundamental catalyst.

What to Watch Going Forward

Analyst targets generally look out about 12 months. Key items include regulatory feedback from the FDA and MHRA on setrusumab, any further data readouts from the Orbit and Cosmic studies, partnering updates for alvelestat, quarterly cash updates, and potential revisions to analyst targets. Earnings releases will matter mainly for cash-burn trends and strategic commentary rather than near-term revenue.

Monitoring with AI Tools

I also checked this using Tickeron’s AI Trend Prediction Engine to gauge how the technical setup compares with historical patterns in similar situations.

AI Daily Buy/Sell Signals

Tickeron’s AI Daily Buy/Sell Signals apply artificial intelligence to track thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on evolving market conditions, technical factors, and AI analysis. For a volatile name like MREO, where clinical and regulatory news can shift sentiment rapidly, the tool helps identify opportunities, track positions, and spot trend changes more efficiently than manual checks alone. Traders often combine these signals with their own research to stay responsive in fast-moving markets.

Final Assessment

Reaching the $1.60 mean target would require a roughly 450% advance from current levels near $0.29—a very large move that cannot be taken for granted. The supporting case rests on the strong BMD secondary endpoint, FDA openness to alternative analyses, a mid-2027 cash runway, and optionality around alvelestat. The counter-case centers on the missed primary fracture endpoints, ongoing regulatory risk, possible dilution, and limited control over the setrusumab program. With targets spanning $0.50 to $3.00, analyst views remain sharply divided, and upcoming regulatory and partnering milestones will decide whether any re-rating can begin.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume